SG x 5: Cinco indicaciones de KEYTRUDA en Cáncer de Pulmón

IR = índice de riesgo; SG = sobrevida global;

Referencia:
  1. J.E. Gray, D. Rodriguez-Abreu, S.F. Powell y cols. Pembrolizumab plus pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. Presented virtually at the 2020 World Conference on Lung Cancer (WCLC). January 28-31, 2021.
  2. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Cid JR, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B, A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407, Journal of Thoracic Oncology (2020), doi: https://doi.org/10.1016/j.jtho.2020.06.015.
  3. B.C. Cho, Y-L. Wu, G. Lopes y cols. KEYNOTE-042 3-year survival update: 1L Pembrolizumab vs. chemotherapy for PD-L1- positive locally advanced or metastatic NSCLC. Presented virtually at the 2020 World Conference on Lung Cancer (WCLC). January 28-31,
  4. Brahmer J. R., Rodriguez-Abreu D., Robinson A. G., y cols. KEYNOTE-024-5-Year OS Update: First-Line Pembrolizumab vs. Platinum-Based Chemotherapy in Patients with Metastatic Non-Small- Cell Lung Cancer and PD-L1 Tumor Proportion Score ≥ 50%. Presented at ESMO Virtual Congress, 15-23 September, 2020. 5. R. S.
    Herbst, E.B. Garon, D.W. Kim y cols. 5-year survival update from KEYNOTE-010: Pembrolizumab versus docetaxel in previously treated, PD-L1-positive advanced NSCLC. Presented virtually at the 2020 World Conference on Lung Cancer (WCLC). January 28-31, 2021.